Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 29,042 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disease;Neurological Clear all

Conditions: Brain Death
Interventions: venous blood gas; Procedure
Lead sponsor: MemorialCare Health System; Other
Eligibility: 1 Week and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Radiation Retinopathy, Visual Impairment
Interventions: Faricimab, fluocinolone acetonide; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 29
States / cities: Palo Alto, California • Manchester, Connecticut • Tampa, Florida + 24 more

Conditions: Phantom Limb Pain
Interventions: Perineural infusion [continuous peripheral nerve block(s)]; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Palo Alto, California • San Diego, California • Bethesda, Maryland + 1 more

Conditions: Syncope, Pediatric, Congenital Athymia, Congenital Heart Disease, Arrhythmia, Arrhythmia in Children
Interventions: Zio monitor; Device
Lead sponsor: iRhythm Technologies, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boise, Idaho • Boston, Massachusetts + 1 more

Conditions: Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome, Chronic Soft Tissue Pain
Interventions: HZT-501; Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Chicago, Illinois • Morton Grove, Illinois • Duncansville, Pennsylvania + 1 more

Conditions: Frailty, Sarcopenia, Sarcopenia in Elderly, Muscle Strength, Post Operative Complications, Nutrition Assessment, Risk Assessment, Elderly (People Aged 65 or More), Hand Strength
Interventions: Frailty assessment, nutrition assessment, cognition assessment, muscle strength testing; Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 65 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: PD - Parkinson's Disease
Interventions: Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001); Combination Product
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Cerebral Palsy
Interventions: Robotic Exoskeleton Gait Therapy, Physical Therapy; Behavioral
Lead sponsor: Father Flanagan's Boys' Home; Other
Eligibility: 14 Years to 30 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boys Town, Nebraska

Conditions: Parkinson Disease, Essential Tremor, Dystonia, Obsessive Compulsive Disorder
Interventions: Functional Magnetic Resonance Imaging (fMRI); Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: PIK3CA-Related Overgrowth Spectrum (PROS)
Interventions: alpelisib; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain, Postoperative, Atrial Fibrillation, Cognitive Dysfunction
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neurogenic Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease
Interventions: Midodrine, Placebo pill, Abdominal compression, sham compression; Drug · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Frontotemporal Dementia
Interventions: Syntocinon; Drug
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's; Other
Eligibility: 30 Years to 80 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Baltimore, Maryland + 2 more

Conditions: Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Interventions: Tovaxin; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: Not listed
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more

Conditions: Major Depressive Disorder, Anhedonia
Interventions: Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Parkinson Disease, Freezing of Gait
Interventions: Multiple Deep Brain Stimulation (DBS) Conditions, Moving Overground in a Virtual Environment (MOVE), Cleveland Clinic Stair Ambulation and Functional Evaluation of Gait (SAFE-Gait); Other · Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions: Sublingual film containing Igalmi; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Little Rock, Arkansas • Rogers, Arkansas

Conditions: Alzheimer Disease, Cognitive Decline, Aging
Interventions: California Cognitive Assessment Battery; Diagnostic Test
Lead sponsor: Neurobehavioral Systems, Inc.; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
Interventions: surgical procedure, astatine At 211 monoclonal antibody 81C6; Procedure · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Parkinson Disease, Dysarthria, Hypokinetic
Interventions: Clear Speech, Less Clear Speech; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Spina Bifida, Myelomeningocele
Interventions: Transcutaneous stimulator; Device
Lead sponsor: Bailey Petersen; Other
Eligibility: 4 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Preclinical Alzheimer's Disease
Interventions: Obicetrapib 10 mg, Matching placebo tablets; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Spinal Cord Injury
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1991 – 2040
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
Interventions: Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG); Biological · Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 0 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts

Search by objective public record fields.

Does Venous pCO2 Increase by 20 mmHg or More During Apnea Challenge Test?

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

Pediatric Adhesion and New Dermal Approach Study

Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment

Frailty and Muscle Strength Tests in Older Adults Undergoing Major Surgery

Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)

Robotic Exoskeleton Gait Training in Adolescents With Cerebral Palsy

Functional Magnetic Resonance Imaging (fMRI) During Deep Brain Stimulation (DBS) to Treat Parkinson's Disease

Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

BRS and Outcomes in Cardiothoracic Surgery

Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients

Intranasal Oxytocin for Frontotemporal Dementia

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

Investigating the Causal Role of Prefrontal Control in Decision-making in Patients With Anhedonia

Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors

A Multidimensional Study on Articulation Deficits in Parkinsons Disease

tSCS in Children With Spina Bifida

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

Male Fertility Program

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG